Literature DB >> 9401507

Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM.

E Ortqvist1, A Falorni, A Scheynius, B Persson, A Lernmark.   

Abstract

Most IDDM patients temporarily restore some of their beta-cell function following the initiation of insulin therapy. The aim of this study was to analyse the influence of age, gender, metabolic state at diagnosis and presence of autoantibodies (GAD65 antibodies and ICA) on the duration of the clinical partial remission. In total, 149 consecutively diagnosed IDDM children, 0-16 y old (70F, 79M, mean age 9.5 y) were studied. Partial remission was arbitrarily defined as the period when the insulin dose was below 0.5 U/BW 24 h-1 and HbA1c below 7.5%, and occurred in 119/149 patients with a duration between 1 and 38 months. Cox's regression analysis showed that the factors significantly associated with the duration of remission were age, gender, interaction between age and gender, ICA and a high initial HbA1c, whereas GAD65Ab had no influence. Young boys had the shortest remission period, while adolescent boys had the longest, as compared to young and adolescent girls. The ICA-negative patients (n = 42) had a longer remission period (median 9.7 months) than the ICA-positive children (n = 107; 5.0 months; p = 0.0001), regardless of GAD65Ab status. We speculate that the relative insulin resistance, which is more pronounced in pubertal girls than in boys, may be associated with a more rapid increase of exogenous insulin requirement. These findings are important when evaluating the effect of islet cell autoreactivity on the clinical course of IDDM in children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401507     DOI: 10.1111/j.1651-2227.1997.tb14837.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  5 in total

1.  Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes.

Authors:  A Blasetti; C Di Giulio; S Tumini; M Provenzano; D Rapino; L Comegna; G Prezioso; R Chiuri; S Franchini; F Chiarelli; L Stuppia
Journal:  Pharmacogenomics J       Date:  2016-02-23       Impact factor: 3.550

2.  Gene CNVs and protein levels of complement C4A and C4B as novel biomarkers for partial disease remissions in new-onset type 1 diabetes patients.

Authors:  Suzanne E Kingery; Yee Ling Wu; Bi Zhou; Robert P Hoffman; C Yung Yu
Journal:  Pediatr Diabetes       Date:  2011-12-13       Impact factor: 4.866

3.  Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions.

Authors:  Benjamin Udoka Nwosu
Journal:  Eur Med J Diabetes       Date:  2019-03-14

4.  Factors Influencing Frequency and Duration of Remission in Children and Adolescents Newly Diagnosed with Type 1 Diabetes.

Authors:  Özlem Kara; İhsan Esen; Derya Tepe
Journal:  Med Sci Monit       Date:  2018-08-28

5.  New definition for the partial remission period in children and adolescents with type 1 diabetes.

Authors:  Henrik B Mortensen; Philip Hougaard; Peter Swift; Lars Hansen; Reinhard W Holl; Hilary Hoey; Hilde Bjoerndalen; Carine de Beaufort; Francesco Chiarelli; Thomas Danne; Eugen J Schoenle; Jan Aman
Journal:  Diabetes Care       Date:  2009-05-12       Impact factor: 17.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.